CSIMarket Company Name, Ticker, Customers, else..
 
Maia Biotechnology Inc   (NYSE: MAIA)
Other Ticker:  
 
 
Price: $1.5500 $-0.03 -1.899%
Day's High: $1.6301 Week Perf: -1.9 %
Day's Low: $ 1.55 30 Day Perf: -17.11 %
Volume (M): 38 52 Wk High: $ 5.99
Volume (M$): $ 59 52 Wk Avg: $2.67
Open: $1.59 52 Wk Low: $1.46



 Market Capitalization (Millions $) 37
 Shares Outstanding (Millions) 24
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -26
 Cash Flow (TTM) (Millions $) 3
 Capital Exp. (TTM) (Millions $) 0

Maia Biotechnology Inc
Maia Biotechnology Inc is a biotechnology company that focuses on developing novel therapies for cancer. The company combines expertise in genomics, bioinformatics, and drug discovery to identify and target key genes and pathways involved in various cancers. Maia Biotechnology's goal is to create innovative treatments that have the potential to improve patient outcomes and revolutionize cancer care.


   Company Address: 444 West Lake Street Chicago 60606 IL
   Company Phone Number: 416-8592   Stock Exchange / Ticker: NYSE MAIA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -6.5%    
CARM        2.75% 
CELU        18.32% 
KZR        1.91% 
MEIP   -5.37%    
MRUS        0.75% 
• View Complete Report
   



Stocks on the Move

MAIA Biotechnologys Telomere Targeting Functionality Enhances Cancer Treatment

Published Fri, Jun 28 2024 4:53 AM UTC

In recent years, MAIA Biotechnology, Inc. (NYSE American: MAIA) has emerged as a leading player in the field of targeted immunotherapies for cancer. With a focus on telomere-targeting functionality, the company s groundbreaking approach is paving the way for more effective and personalized cancer treatments. With recent achievements and FDA approval of a telomerase inhibitor...
Maia Biotechnology Inc

Maia Biotechnology Inc Reports Encouraging Improvements in Third Quarter 2023 Performance Amidst Sector-Wide Earnings Releases

The Major Pharmaceutical Preparations sector has been in the spotlight as various companies release their earnings for the reporting season that spans from July to September 30, 2023. One such company is Maia Biotechnology Inc (MAIA), which recently announced an operating shortfall of $-4.955643 million for the most recent fiscal period.
It is evident that Maia Biotechnology Inc, an emerging growth entity, has been working more efficiently compared to the third quarter of 2022 when it reported an operating shortfall of $-5.095586 million. During the interval from July to September 30, 2023, the management of Maia has made significant strides in improving the company's performance, reducing losses to $-4.876 million.
Maia Biotechnology Inc

Maia Biotechnology Inc Faces High Stakes as Operating Deficit Surges in Q2 2023

In the highly competitive Major Pharmaceutical Preparations sector, even smaller entities like Maia Biotechnology Inc are feeling the pinch and reporting disappointing earnings. The company recently announced a staggering operating deficit of $-4.664646 million for the second quarter of 2023, a significant decrease from the operating deficit of $-3.442044 million in the same period last year. This puts Maia Biotechnology Inc in a precarious position as they struggle to find a sustainable financial footing.
Management at Maia Biotechnology Inc is actively implementing various corporate policies in an effort to generate consistent revenue streams. However, their efforts seem to be in vain as the net loss for the emerging period has risen from $-3.306 million in Q2 of 2022 to a distressing $-4.524 million this year. This downward trajectory raises serious concerns about the company's financial stability and its ability to turn things around in the near future.
Maia Biotechnology Inc

Maia Biotechnology Inc Reveals Operating Deficit of $4.18 Million in Q1 2023, Causing Concern Among Shareholders

Maia Biotechnology Inc, a prominent player in the biotech industry, has recently reported an operating deficit of $-4.18425 million during the earnings cycle of fiscal January to March 31, 2023. This has come as concerning news to shareholders, who did not assume any adjustments at the top-line during the reporting season. While this deficit has been a cause of worry, it is important to note that it is not something that has not been witnessed in the industry before.
Maia Biotechnology Inc has reported a net shortfall of $-4.117 million in the first quarter of 2023, which is a concerning figure when compared to the balanced books reported in the comparable reporting season a year ago. However, it is important to note that several factors could have led to this deficit, including a slowdown in business due to the ongoing pandemic and increasing competition in the industry.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com